Carmat : The human heart
The first results on survival rates for Carmat’s artificial heart are convincing and should enable the group to obtain EC labelling by H1 2021 for a launch in Europe at end-2021 and in the US at end-2024, on our reckoning (more conservative than management). We think that the real challenge lies in Carmat’s production capacity to meet medium-/long-term demand. Our valuation by DCF, including an increase in capex and WCR, reveals a target price of € 27. We are therefore initiating...Carmat is focused on the research and development of an innovative product in the medical sector, developing an orthotopic and biocompatible artificial heart which is completely implantable, as well as its electrical power supply system and remote diagnosis system. Co. is developing a long-term therapeutic solution for patients who suffer from advanced bi-ventricular heart failure and who are not eligible for cardiac transplantation and who have exhausted all drug possibilties. Co. is still in the phase of research and development and thus do not generate any revenues.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.